COVID-19
Shionogi Still Hopeful For Xocova In US Despite Phase III Fail
Despite sales success in Japan and a fast track designation in the US, Shionogi’s oral COVID-19 therapeutic has missed statistical significance in a global Phase III trial in patients with mild to moderate symptoms.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: AstraZeneca’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer partners up for respiratory therapy.
Sanofi’s $500m COVID-19 Deal Comes Four Years Too Late
But it rescues embattled Novavax.
A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up
The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.
Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call
Pfizer’s management team addressed topics ranging from COVID-19 revenues to Medicare’s drug negotiation program and new product launches.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
InflaRx Picks Outcomes-Based Reimbursement For COVID-19 Drug
The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.
Stock Watch: Vaccines, Oncology Frame Q4 Contrasts Between Pfizer And GSK
While attempting to move beyond post-pandemic unfavorable revenue comparisons, other unfavorable comparisons emerged at Pfizer.
Drug Spending Trends Seem To Be Past Pandemic Effects, IQVIA Medicine Use Report Says
A shift in the mix of drugs is helping to drive market growth, while geopolitical conflict and climate change are having effects as well, with climate change likely to become more disruptive.
Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?
Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.
Stock Watch: After The Pandemic, Different Vaccines To The Rescue
From the unfavorable comparisons brought about by lower pandemic-related product sales, vaccines for other diseases bring hopes for longer-term success.
Abrysvo Launch A Bright Spot For Pfizer In A Third Quarter Reset
The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.
‘It’s A Very Different Story,’ Pfizer CEO Bourla Says Of Cuts To Match COVID Revenue
The company lowered Paxlovid and Comirnaty 2023 revenue projections by $9bn, announced plans for the commercial transition of the products, and revealed a cost-cutting plan.
Moderna Marches Into Phase III With COVID/Flu Vaccine Combo
The US biotech major says that preliminary data show that its mRNA-1083 combination vaccine yielded antibody levels in the blood similar to or greater than two Sanofi flu vaccines and its own COVID-19 shot Spikevax.
Moderna Shows Ambition With Flu Success And Cancer Therapy Expansion
Slower COVID-19 vaccine sales will see Moderna’s revenues decline this year, but the company is investing heavily to speed a new wave of therapies to the market.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.